194 related articles for article (PubMed ID: 19319477)
1. Experience with long-term treatment with albumin-supplemented botulinum toxin type A.
Mohammadi B; Kollewe K; Wegener M; Bigalke H; Dengler R
J Neural Transm (Vienna); 2009 Apr; 116(4):437-41. PubMed ID: 19319477
[TBL] [Abstract][Full Text] [Related]
2. Safety, effectiveness, and duration of effect of BOTOX after switching from Dysport for blepharospasm, cervical dystonia, and hemifacial spasm dystonia, and hemifacial spasm.
Bihari K
Curr Med Res Opin; 2005 Mar; 21(3):433-8. PubMed ID: 15811212
[TBL] [Abstract][Full Text] [Related]
3. Long-term efficacy and safety of botulinum toxin A injections to treat blepharospasm and hemifacial spasm.
Ababneh OH; Cetinkaya A; Kulwin DR
Clin Exp Ophthalmol; 2014 Apr; 42(3):254-61. PubMed ID: 23844601
[TBL] [Abstract][Full Text] [Related]
4. Low-dose treatment of cervical dystonia, blepharospasm and facial hemispasm with albumin-diluted botulinum toxin type A under EMG guidance. An open label study.
Rollnik JD; Matzke M; Wohlfarth K; Dengler R; Bigalke H
Eur Neurol; 2000; 43(1):9-12. PubMed ID: 10601802
[TBL] [Abstract][Full Text] [Related]
5. [Botulinum toxin therapy for focal dystonia].
Hahn K; Niklai E; Garzuly F; Szupera Z
Orv Hetil; 2009 Jul; 150(29):1381-4. PubMed ID: 19581172
[TBL] [Abstract][Full Text] [Related]
6. Effectivity of Dysport in patients with blepharospasm and hemifacial spasm who experienced failure with Botox.
Badarny S; Susel Z; Honigman S
Isr Med Assoc J; 2008 Jul; 10(7):520-2. PubMed ID: 18751631
[TBL] [Abstract][Full Text] [Related]
7. Outcome predictors, efficacy and safety of Botox and Dysport in the long-term treatment of hemifacial spasm.
Bentivoglio AR; Fasano A; Ialongo T; Soleti F; Lo Fermo S; Albanese A
Eur J Neurol; 2009 Mar; 16(3):392-8. PubMed ID: 19364366
[TBL] [Abstract][Full Text] [Related]
8. Switch from abobotulinumtoxinA (Dysport®) to incobotulinumtoxinA (Xeomin®) botulinum toxin formulation: a review of 257 cases.
Grosset DG; Tyrrell EG; Grosset KA
J Rehabil Med; 2015 Feb; 47(2):183-6. PubMed ID: 25325305
[TBL] [Abstract][Full Text] [Related]
9. Dose conversion ratio, comparative efficacy, and adverse events after switching from onabotulinum toxin A to abobotulinum toxin A for neurological conditions.
Ozer IS; Kuzu Kumcu M; Tezcan Aydemir S; Akbostanci MC
Clin Neurol Neurosurg; 2021 Oct; 209():106889. PubMed ID: 34461363
[TBL] [Abstract][Full Text] [Related]
10. Fifteen-year experience in treating blepharospasm with Botox or Dysport: same toxin, two drugs.
Bentivoglio AR; Fasano A; Ialongo T; Soleti F; Lo Fermo S; Albanese A
Neurotox Res; 2009 Apr; 15(3):224-31. PubMed ID: 19384595
[TBL] [Abstract][Full Text] [Related]
11. [Essential blepharospasm and hemifacial spasm: characteristic of the patient, botulinum toxin A treatment and literature review].
Schellini SA; Matai O; Igami TZ; Padovani CR; Padovani CP
Arq Bras Oftalmol; 2006; 69(1):23-6. PubMed ID: 16491229
[TBL] [Abstract][Full Text] [Related]
12. Comparison of techniques of botulinum toxin injections for blepharospasm and hemifacial spasm.
Sacramento DRC; Lima A; Maia DP; Cunningham M; Maciel RH; Camargos ST; Cardoso F
Mov Disord; 2019 Sep; 34(9):1401-1403. PubMed ID: 31251420
[No Abstract] [Full Text] [Related]
13. Long-term efficacy of botulinum toxin A for treatment of blepharospasm, hemifacial spasm, and spastic entropion: a multicentre study using two drug-dose escalation indexes.
Cillino S; Raimondi G; Guépratte N; Damiani S; Cillino M; Di Pace F; Casuccio A
Eye (Lond); 2010 Apr; 24(4):600-7. PubMed ID: 19648904
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of carbamazepine combined with botulinum toxin a in the treatment of blepharospasm and hemifacial spasm.
Li XH; Lin SC; Hu YF; Liu LY; Liu JB; Hong YC
Eye Sci; 2012 Dec; 27(4):178-81. PubMed ID: 23225838
[TBL] [Abstract][Full Text] [Related]
15. DYSBOT: a single-blind, randomized parallel study to determine whether any differences can be detected in the efficacy and tolerability of two formulations of botulinum toxin type A--Dysport and Botox--assuming a ratio of 4:1.
Sampaio C; Ferreira JJ; Simões F; Rosas MJ; Magalhães M; Correia AP; Bastos-Lima A; Martins R; Castro-Caldas A
Mov Disord; 1997 Nov; 12(6):1013-8. PubMed ID: 9399229
[TBL] [Abstract][Full Text] [Related]
16. Long-term botulinum toxin treatment of benign essential blepharospasm, hemifacial spasm, and Meige syndrome.
Czyz CN; Burns JA; Petrie TP; Watkins JR; Cahill KV; Foster JA
Am J Ophthalmol; 2013 Jul; 156(1):173-177.e2. PubMed ID: 23541393
[TBL] [Abstract][Full Text] [Related]
17. Botulinum toxin: evidence-based medicine criteria in blepharospasm and hemifacial spasm.
Jost WH; Kohl A
J Neurol; 2001 Apr; 248 Suppl 1():21-4. PubMed ID: 11357234
[TBL] [Abstract][Full Text] [Related]
18. Quality of life in hemifacial spasm patient after treatment with botulinum toxin A; a 24-week, double-blind, randomized, cross-over comparison of Dysport and Neuronox study.
Kongsengdao S; Kritalukkul S
J Med Assoc Thai; 2012 Mar; 95 Suppl 3():S48-54. PubMed ID: 22619887
[TBL] [Abstract][Full Text] [Related]
19. Dysport (botulinum toxin type A) in routine therapeutic usage: a telephone needs assessment survey of European physicians to evaluate current awareness and adherence to product labeling changes.
Hubble J; Schwab J; Hubert C; Abbott CC
Clin Neuropharmacol; 2013; 36(4):122-7. PubMed ID: 23783005
[TBL] [Abstract][Full Text] [Related]
20. A comparative crossover study on the treatment of hemifacial spasm and blepharospasm: preseptal and pretarsal botulinum toxin injection techniques.
Lolekha P; Choolam A; Kulkantrakorn K
Neurol Sci; 2017 Nov; 38(11):2031-2036. PubMed ID: 28884242
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]